Loading…
Biotech that withdrew its ALS drug Relyvrio in 2024 and pivoted pipeline toward avexitide for hypoglycemia disorders.
Biotech that withdrew its ALS drug Relyvrio in 2024 and pivoted pipeline toward avexitide for hypoglycemia disorders.
Has no product on sale since it withdrew Relyvrio, its ALS drug, so it earns no product revenue and lives on cash from that drug's earlier sales. Its spending now goes to avexitide, a drug aimed at dangerously low blood sugar after weight-loss surgery.
Moat: none (IP / patents). Lost its only approved product; must re-prove itself with a new pipeline.
Headquarters: Cambridge, Massachusetts, US · Founded: 2019 · Employees: 136
Size Amylyx Pharmaceuticals (AMLX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $3.70B, the 1395th largest of 3,117 United States companies the cockpit tracks. Shares closed at $29.50 on 6 Nov 2026.
Performance Over six months the shares gained 96.9%, against +2.0% for the median peer and -1.1% for the United States market (cap-weighted) — highest of 20 in its peer set.
Growth Revenue grew 100.0% over the last twelve months (peer median +4.5%).
Short interest Short interest is 10.6% of the free float (15 Oct 2026).
Next results Next results expected around 9 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $87.4M | $381M | $22.2M |
| Revenue growth | — | -100% | -77% | +1,613% | — |
| Gross profit | -$369,000 | -$525,000 | -$38.2M | $354M | $18.8M |
| EBITDA | -$162M | -$153M | -$255M | $39.9M | -$201M |
| Net income | -$152M | -$145M | -$302M | $49.3M | -$198M |
| Free cash flow | -$127M | -$123M | -$168M | $10.7M | -$182M |
| Capital expenditure | $4.14M | $138,000 | $36.4M | $1.24M | $2.53M |
| Total debt | $5.25M | $5.96M | $1.98M | $4.24M | $6.28M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Amylyx Pharmaceuticals AMLX | $3.70B | +97% | +100% | n/a | n/a | n/a |
| Zealand Pharma A/S ZEAL.CO | $2.32B | -32% | -49% | 51% | 0.3× | n/a |
| Rezolute RZLT | $375M | +21% | n/a | n/a | n/a | n/a |
| Amgen AMGN | $249B | +40% | +9% | 36% | 7.4× | 1.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AMLX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +30.1% | +5.2% | 2nd highest of 21 |
| 6-month return | +96.9% | +2.0% | highest of 20 |
| Distance from 52-week high | -3.8% | -24.8% | 3rd highest of 21 |
| Revenue growth (TTM) | +100.0% | +4.5% | 3rd highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Amylyx Pharmaceuticals AMLX | United States | $3.70B | +97% | +100% | n/a | n/a | n/a | n/a |
| Livzon Pharmaceutical 000513.SZ | China | $3.71B | -4% | -14% | 19% | 2.2× | -9.8% | +2.7% |
| Apeloa Pharmaceutical 000739.SZ | China | $3.73B | +18% | -16% | 10% | 2.8× | 6.3% | +4.5% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.74B | -11% | +8% | 4% | 0.6× | -5.3% | +7.8% |
| ACADIA Pharmaceuticals ACAD | United States | $3.66B | -5% | +12% | 8% | 2.4× | 16.7% | +19.4% |
| Organon & OGN | United States | $3.64B | +4% | -3% | 20% | 1.8× | -4.5% | -1.0% |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.63B | -7% | +27% | 18% | 2.7× | -2.8% | +10.6% |
| Xenon Pharmaceuticals XENE | United States | $3.79B | +4% | -100% | n/a | n/a | n/a | n/a |
| Suzhou Zelgen Biopharmaceuticals 688266.SS | China | $3.60B | -13% | +136% | 29% | 12.8× | 20.5% | +98.4% |
| Santen Pharmaceutical 4536.T | Japan | $3.86B | +17% | -1% | 16% | 1.9× | -5.2% | +3.2% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.86B | +8% | +10% | 12% | 3.4× | 7.3% | +5.9% |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.89B | +15% | +3% | 20% | 4.5× | 1.5% | +12.1% |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.47B | +2% | +3% | 19% | 3.1× | -2.2% | +12.0% |
| Liquidia LQDA | United States | $3.97B | +5% | +2,234% | 37% | 8.6× | 0.7% | +192.5% |
| Siegfried SFZN.SW | Switzerland | $3.98B | -10% | +4% | 16% | 3.0× | n/a | n/a |
| Viking Therapeutics VKTX | United States | $3.42B | -17% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Henlius Biotech 2696.HK | Hong Kong | $3.41B | -37% | +33% | 12% | 3.7× | 15.2% | +61.4% |
| Yuhan 000100.KS | South Korea | $4.05B | -12% | +5% | 5% | 2.4× | 20.2% | +6.2% |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.05B | +6% | -4% | 32% | 2.8× | -11.5% | +0.3% |
| Tarsus Pharmaceuticals TARS | United States | $3.38B | +12% | +86% | -10% | 4.6× | 31.9% | +159.5% |